Article (Scientific journals)
Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.
Chiavarina, Barbara; Ronca, Roberto; Otaka, Yukihiro et al.
2022In Oncogene, 41 (10), p. 1410-1420
Peer Reviewed verified by ORBi
 

Files


Full Text
s41388-021-02171-z.pdf
Publisher postprint (4.99 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Cancer-associated fibroblasts (CAF) are important constituents of the tumor microenvironment (TME) and are major drivers of tumorigenesis. Yet, therapies aiming at eliminating CAF have failed to cure patients. This setback has raised questions regarding whether CAF exclusively favour cancer progression, or if they may also assume tumor-suppressor functions. In the present study, we used proteomics and single cell RNA-sequencing analysis to examine the CAF landscape in hepatocellular carcinoma (HCC). We thereby unveil three major CAF populations in HCC, one of which specifically expressing the prolargin protein. This CAF subpopulation (further termed as CAF_Port) shared a strong transcriptomic signature with portal liver fibroblasts. We further show that CAF_Port deposit prolargin in the TME and that its levels are lower in tumors as compared to the peritumoral region. Mechanistically, aggressive cancer cells degraded prolargin using matrix metalloprotease activity. Survival analysis of 188 patients revealed that high prolargin protein levels correlate with good patient outcome (HR = 0.37; p = 0.01). In vivo, co-injection of cancer cells with fibroblasts silenced for prolargin, led to faster tumor development (5-fold; p = 0.01), mainly due to stronger angiogenesis. Using protein-protein interaction study and structural modelling, we further demonstrate that prolargin binds and inhibits the activity of several pro-agiogenic proteins, including hepatocyte and fibroblast growth factors. In conclusion, prolargin is angiogenesis modulator and CAF-derived tumor suppressor in HCC. Stabilizing prolargin levels in the CAF_Port subpopulation may revert their tumor-antagonizing properties, warranting exploration in further pre-clinical studies.
Disciplines :
Surgery
Gastroenterology & hepatology
Author, co-author :
Chiavarina, Barbara
Ronca, Roberto
Otaka, Yukihiro
Sutton, Roger Bryan
Rezzola, Sara
Yokobori, Takehiko
Chiodelli, Paola
Souche, Regis
Pourquier, Didier
Maraver, Antonio
Faa, Gavino
Khellaf, Lakhdar
Turtoi, Evgenia
Oyama, Tetsunari
Gofflot, Stéphanie ;  Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Bellahcene, Akeila ;  Université de Liège - ULiège > GIGA Cancer - Metastases Research Laboratory
Detry, Olivier  ;  Université de Liège - ULiège > Département des sciences cliniques > Pathologie chirurgicale abdominale et endocrinienne
Delvenne, Philippe ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Castronovo, Vincent
Nishiyama, Masahiko
Turtoi, Andrei
More authors (11 more) Less
Language :
English
Title :
Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.
Publication date :
March 2022
Journal title :
Oncogene
ISSN :
0950-9232
eISSN :
1476-5594
Publisher :
Nature Publishing Group, United Kingdom
Volume :
41
Issue :
10
Pages :
1410-1420
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Available on ORBi :
since 18 January 2022

Statistics


Number of views
80 (24 by ULiège)
Number of downloads
6 (4 by ULiège)

Scopus citations®
 
15
Scopus citations®
without self-citations
14
OpenCitations
 
3

Bibliography


Similar publications



Contact ORBi